Livzon Pharmaceutical Group Inc (000513) — Capital Reinvestment Ratio
Livzon Pharmaceutical Group Inc (000513) has a Capital Reinvestment Ratio of 0.13x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥625.70 Million) in capital expenditures (CN¥78.72 Million). Check Livzon Pharmaceutical Group Inc (000513) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Livzon Pharmaceutical Group Inc Capital Reinvestment Ratio (1999–2025)
This chart tracks Livzon Pharmaceutical Group Inc's Capital Reinvestment Ratio across 27 annual periods. For the full cash flow conversion analysis, see 000513 cash flow conversion.
Annual Capital Reinvestment Ratio for Livzon Pharmaceutical Group Inc (1999–2025)
Year-by-year Capital Reinvestment Ratio for Livzon Pharmaceutical Group Inc from 1999 to 2025. See 000513 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.18x | CN¥3.18 Billion | CN¥574.14 Million | ▼ -5.6% |
| 2024 | 0.19x | CN¥2.98 Billion | CN¥570.16 Million | ▼ -24.2% |
| 2023 | 0.25x | CN¥3.25 Billion | CN¥820.45 Million | ▼ -25.5% |
| 2022 | 0.34x | CN¥2.77 Billion | CN¥940.15 Million | ▼ -50.7% |
| 2021 | 0.69x | CN¥1.90 Billion | CN¥1.31 Billion | ▲ +129.8% |
| 2020 | 0.30x | CN¥2.16 Billion | CN¥646.98 Million | ▲ +32.9% |
| 2019 | 0.23x | CN¥1.77 Billion | CN¥398.00 Million | ▼ -39.8% |
| 2018 | 0.37x | CN¥1.27 Billion | CN¥474.47 Million | ▲ +67.4% |
| 2017 | 0.22x | CN¥1.32 Billion | CN¥294.15 Million | ▼ -22.4% |
| 2016 | 0.29x | CN¥1.28 Billion | CN¥368.46 Million | ▼ -44.0% |
| 2015 | 0.51x | CN¥927.79 Million | CN¥477.13 Million | ▼ -44.6% |
| 2014 | 0.93x | CN¥717.39 Million | CN¥665.52 Million | ▼ -55.6% |
| 2013 | 2.09x | CN¥439.99 Million | CN¥920.00 Million | ▲ +62.9% |
| 2012 | 1.28x | CN¥593.96 Million | CN¥762.30 Million | ▲ +160.6% |
| 2011 | 0.49x | CN¥708.20 Million | CN¥348.83 Million | ▼ -7.4% |
| 2010 | 0.53x | CN¥633.30 Million | CN¥336.95 Million | ▲ +100.4% |
| 2009 | 0.27x | CN¥494.88 Million | CN¥131.41 Million | ▲ +21.4% |
| 2008 | 0.22x | CN¥345.18 Million | CN¥75.52 Million | ▼ -40.4% |
| 2007 | 0.37x | CN¥248.55 Million | CN¥91.28 Million | ▼ -53.9% |
| 2006 | 0.80x | CN¥226.46 Million | CN¥180.45 Million | ▼ -50.0% |
| 2005 | 1.59x | CN¥161.07 Million | CN¥256.72 Million | ▲ +97.4% |
| 2004 | 0.81x | CN¥181.46 Million | CN¥146.48 Million | ▲ +133.9% |
| 2003 | 0.35x | CN¥300.01 Million | CN¥103.56 Million | ▼ -28.8% |
| 2002 | 0.48x | CN¥213.65 Million | CN¥103.62 Million | ▼ -7.7% |
| 2001 | 0.53x | CN¥155.15 Million | CN¥81.48 Million | ▼ -67.1% |
| 2000 | 1.60x | CN¥38.52 Million | CN¥61.49 Million | ▲ +435.3% |
| 1999 | 0.30x | CN¥246.23 Million | CN¥73.44 Million | — |